Denosumab-induced hypocalcemia in patients with solid tumors and renal dysfunction: a multicenter, retrospective, observational study

Bone metastases are frequently observed in advanced cancer, and bone modifying agents are used to prevent or treat skeletal-related events. Zoledronic acid is contraindicated in patients with severe renal impairment (Ccr

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	BMC cancer 2024-02, Vol.24 (1), p.218-218, Article 218
Hauptverfasser:	Nakamura, Kazuyo, Kaya, Michihiro, Yanagisawa, Yuki, Yamamoto, Keisuke, Takayashiki, Nana, Ukita, Hirotoshi, Nagura, Mariko, Sugiue, Kaori, Kitajima, Mariko, Hirano, Kumi, Ishida, Hiroki, Onoda, Chiharu, Kobayashi, Yutaka, Nakatani, Eiji, Odagiri, Keiichi, Suzuki, Takaya
Format:	Artikel
Sprache:	eng
Schlagworte:	Acids Albumin Bone cancer Bone metastases Bone tumors Calcium Calcium (blood) Cancer therapies Care and treatment Chronic kidney failure Complications and side effects Consent Contraindications Creatinine Denosumab Diagnosis Dosage and administration Drug dosages Hypocalcemia Lung cancer Metastases Metastasis Monoclonal antibodies Patients Prevention Prostate cancer Regression analysis Renal function Renal insufficiency Risk factors Solid tumors Terminology Tumors Vitamin D Zoledronic acid
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Bone metastases are frequently observed in advanced cancer, and bone modifying agents are used to prevent or treat skeletal-related events. Zoledronic acid is contraindicated in patients with severe renal impairment (Ccr
ISSN:	1471-2407 1471-2407
DOI:	10.1186/s12885-024-11942-2